Aleafia Health (TSX: AH) confirmed this morning that, as previously announced, the company has managed to pay of its 8% unsecured convertible debentures that came due today. In total, the payment is believed to have amounted to $25 million.
The company also revealed this morning that it achieved “record cannabis net revenue” in the fourth quarter of 2020 ended December 31, 2020. Full details were not provided by the company, however the company indicated that medical cannabis saw its best quarter to date in Q4, with growth expected to continue, with January seeing its fourth consecutive monthly record for medical cannabis revenue.
For adult-use revenue, the company shifted the goal posts, indicating that the first month of 2021 saw sales so strong that “they nearly surpassed total order value in Q4 2020,” however the total order value for the fourth quarter was not provided, making the data provided unusable. The company also indicated that international sales have continued with new supply agreements, while note product formats are to be launched 2021.
Aleafia Health last traded at $0.73 on the TSX.
Information for this briefing was found via Sedar and Aleafia Health. The author has no affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
Why Public Cannabis CFOs Need to Breakdown and Segment Their Accounts Receivables
Limited Disclosures Risk Signaling Poor Financial Health to Analysts and Investors The ‘accounts receivable to...